Search Results for "ATTR"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Real-world experience with therapeutics for ATTR in the Canadian population

Evidence of Fewer Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran Compared with Placebo: Analysis from HELIOS-B

History of Polyneuropathy and Musculoskeletal Manifestations in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy in APOLLO-B

Impact of vutrisiran on outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial

Cardiovascular Morbidity and Mortality Among ATTR-CM Patients Treated with Tafamidis in the US

ATTR Disease Management

This deck highlights management and monitoring of patients with ATTR.

ATTR Amyloidosis Disease State Handout

This handout provides an overview of ATTR amyloidosis manifestations and the diagnostic tools that can be used to assess their presentation.

ATTR Screening and Carrier

ATTR Screening and Carrier

ATTR Management Guidelines

This deck highlights published guidelines on diagnosis, treatment and disease management of ATTR.

Symptoms and Disease Burden of ATTR

This slide deck provides an overview of the symptoms and disease burden of ATTR.

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.